Abstract
One of the major challenges encountered in translational research applied to rare neurodegenerative diseases (NDs), such as Amyotrophic Lateral Sclerosis (ALS), is the functional evaluation of new variants potentially associated with these diseases. Novel gene variants of uncertain significance (VUS) are often identified in patients with NDs, highlighting the need for functional validatio…